Michael J Fox Foundation backs Alchemab Therapeutics’ Parkinson’s disease program

Alchemab Therapeutics has been awarded a grant of $595,000 by The Michael J Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease programme.

The grant will fund research performed at Alchemab following its identification of antibodies that target prostaglandin biology in Parkinson’s disease (PD), a unique approach to treatment.

Alchemab is researching the therapeutic effects of its resilient patient-derived antibody in PD using its innovative platform which integrates advanced proteomics, bioinformatics, and machine learning in the analysis of patient samples to find signals associated with resilience to disease.

Using samples from patients predisposed to PD symptoms and samples from patients with a typical disease course, Alchemab identified a target it believes may contribute to disease resistance. Its research explores how the prostaglandin pathway impacts disease progression, using comprehensive genetic and molecular analyses.

In addition, it is applying its computation resources to mine large PD datasets like the Parkinson’s Progression Markers Initiative (PPMI) to identify novel targets.

Young Kwon, CEO of Alchemab Therapeutics, said: “We are delighted to be working with The Michael J Fox Foundation whose goals we share of fostering innovative Parkinson’s disease research, enhancing understanding of the disease, and developing targeted therapies.”

Sohini Chowdhury, chief programme officer at MJFF, said: “Alchemab has a unique approach to its research, and we are very much looking forward to seeing how this can identify new biomarkers and explore the role of inhibitory antibodies in Parkinson’s resilient individuals.

“We hope that this work will expand new treatment pathways and bring hope to patients challenged by the disease.”

The grant was awarded through MJFF’s Parkinson’s Disease Therapeutics pipeline programme.